Savara (NASDAQ:SVRA) Shares Gap Down After Earnings Miss

Savara Inc. (NASDAQ:SVRA) shares gapped down prior to trading on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $5.08, but opened at $4.82. Savara shares last traded at $5.06, with a volume of 89,638 shares traded.

The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01).

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Monday, March 16th. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. Finally, William Blair set a $10.00 price target on Savara in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $9.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Polar Capital Holdings Plc purchased a new position in Savara in the fourth quarter worth $50,086,000. RTW Investments LP acquired a new position in shares of Savara during the 4th quarter worth $35,893,000. VR Adviser LLC grew its stake in shares of Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares during the period. Marshall Wace LLP acquired a new stake in shares of Savara in the fourth quarter valued at about $27,496,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Savara in the fourth quarter valued at about $14,539,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Trading Down 0.4%

The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. The business’s fifty day moving average is $5.38 and its 200 day moving average is $5.47. The stock has a market cap of $1.04 billion, a PE ratio of -9.58 and a beta of 0.28.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.